Alterome
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
13480 Evening Creek Drive North Ste 450,...Website
www.alterome.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Alterome
Alterome Therapeutics is a clinical-stage biotechnology company focused on transforming the lives of cancer patients through the discovery of precise therapies. Utilizing a structure-guided approach to drug discovery, the company develops targeted oncology therapies aimed at high-value oncogenic drivers with limited treatment options. Their advanced programs include first-in-class small molecules targeting challenging cancer targets such as AKT and KRAS. Driven by a commitment to innovation and collaboration, Alterome seeks to inspire hope and improve outcomes for individuals affected by cancer.Explore more
Alterome Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alterome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Alterome has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alterome
Check out if Alterome is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Alterome, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Alterome has recently received funding, and reach out quickly before it becomes old news!
Click to see if Alterome had a recent Job posting/layoffs
Product Launch: Get notified when Alterome launches new products
Earning: See what the market has to say on Alterome recently announced quarterly report
Recommended Actions
Find VP level buyers at Alterome
Find 3 more new buyers
Compare Similar Companies to Alterome
Compare insights from companies similar to Alterome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alterome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alterome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alterome.
Alterome financials insights
Gather financial insights about Alterome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$132M
Alterome Tech Stack
A closer look at the technologies used by Alterome
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Hiring Plans
Hiring Plans
Alterome News & Media
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.Alterome Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that senior management will participate in TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Healthcare Conference 2025. Members of Alterome management will participate in one-on-one investor meetings at both conferences. Details of participation areAlterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical stage biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the dosing of the first patient in AKTive-001, a Phase 1/1b trial of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors. ALTA2618 is the first mutant-selective allosteric inhibitor of AKT1 E17K and is designed to avoid on-target toxicities associated with inhibAlterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain. “ALTA3263 induces deep and durable tumor r
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alterome
Sign Up For FreeTo access detailed company insights
Alterome Therapeutics is a clinical-stage biotechnology company focused on transforming the lives of cancer patients through the discovery of precise therapies. Utilizing a structure-guided approach to drug discovery, the company develops targeted oncology therapies aimed at high-value oncogenic drivers with limited treatment options. Their advance... Read More
